Inventiva Sa (IVA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.78 (+0.80%), Market cap $1.12B, 52-week low–high $2.98 ~ $7.15.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Financial statements, price targets, institutional (13F) holdings and related news for Inventiva Sa are updated in real time on BlackAll Trade.
Inventiva Sa trades at $3.78 (+0.80%). Real-time quotes and charts are available on BlackAll Trade.
Inventiva Sa has a market cap of about $1.12B.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and